## **CONTINUING MEDICAL EDUCATION**

## **DIABETES & ITS COMPLICATIONS**

## POST - TEST

Name :	
City :	
Email :	
Q1. According to the latest data given likely to reach an estimate of	n by the International Diabetes Federation (IDF), the prevalence of diabetes is by the year 2045.
☐ A) 629 million	
☐ B) 640 million	
C) 540 million	
D)720 million	
Q2. By the time of clinical diagnosis	of type 2 diabetes, about of beta-cell function is lost.
☐ A) 10–20%	
☐ B) 20–30%	
C) 50–80%	
☐ D)30-40%	
Q3. All of the following form part of	triumvirate in pathophysiology of type 2 diabetes, except:
A) Beta-cell failure	
☐ B) Insulin resistance in muscle	
C) Insulin resistance in liver	
D)Increased glucagon secretion	by alpha-cells
Q4. According to recent ADA 2019 s for identification of prediabetes?	tandards of medical care in diabetes, which of the following represent criteria
A) FPG 100 mg/dL to 125 mg/dl	L
☐ B) 2-h PG in the 75-g OGTT 140	0 mg/dL to 199 mg/dL
☐ C) HbA1c 5.7–6.4%	
D)Any of the above	





Q5. Which of the following is not included in the ADA 2019 crite	eria for the diagnosis of diabetes?
$\square$ A) FPG $\ge 126$ mg/dL	
B) 2-h PG ≥ 200 mg/dL during OGTT	
$\Box$ C) A1c $\geq$ 6.5%	
<ul><li>D)A random plasma glucose ≥ 150 mg/dL in a patient with classis.</li></ul>	assic symptoms of hyperglycemia or hyperglycemic
Q6. All of the following are correct for HbA1c testing, except:	
A) It provides an indirect measure of average blood glucose lefor diagnostic testing.	vels, and is equally appropriate to FPG and 2-h PG
B) Recent ADA 2019 recommendations mention HbA1c three	shold value of $\geq$ 6.5% for the diagnosis of diabetes
C) This HbA1c cut-off (≥6.5%) has high sensitivity, and can cases identified collectively using A1c, FPG, or 2-h PG.	liagnose diabetes in more than 70% of the diabetes
D)Advantages of A1c testing include convenience, applicability, which appear to have facilitated its wide-spread use.	reproducibility  and  standardization  of  measurement,
Q7. Less stringent A1c goals (<8%) may be appropriate for all of	the following patients with diabetes, except:
A) Patients with long life expectancy	
B) Patients with history of severe hypoglycemia	
C) Patients with advanced micro or macrovascular complicat	ions
D) Patients with long-standing diabetes having difficulty in achi	eving glycemic goal despite intensive management.
Q8. Pathway/s implicated in hyperglycemia and oxidative stress include:	mediated development of diabetes complications
A) Polyol pathway flux and overactive hexosamaine pathway	
B) Protein kinase C activation	
C) Increased production of advanced glycation end products	(AGEs)
D)All of the above	
Q9. Diabetes patients taking metformin should undergo vitamin I	312 assessment:
A) Annually	
B) Bi-monthly	
C) Quarterly	
D)Every six months	
Q10. Benfotiamine, a thiamine derivative with anti-AGE effects, is and treatment of diabetes related vascular and neuronal complication the following property/properties of the molecule:	
A) Neurotropic	
☐ B) Cardio and angioprotective	
C) Cytoprotective	Signature:
D)All of the above.	,
	Date:
For official use	
Name of MR:	HQ: